Clinical observation of vinorelbine combined with cisplatin on advanced metastatic breast cancer resisting to anthracycine and taxane
10.3760/cma.j.issn.1008-6706.2010.21.026
- VernacularTitle:长春瑞滨联合顺铂治疗蒽环及紫杉类耐药的晚期转移性乳腺癌
- Author:
Junmin CHEN
;
Xianhe XIE
;
Hua LIU
;
Yanju CHEN
;
Haixia WANG
- Publication Type:Journal Article
- Keywords:
Neoplasm metastasis;
Breast neoplasms;
Antineoplastic combined chemotherapy protocols
- From:
Chinese Journal of Primary Medicine and Pharmacy
2010;17(21):2934-2936
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the efficacy and safety of combination chemotherapy with vinorelbine and cisplatin in the treatment of metastatic breast cancer resisting to anthracycline and taxane.Methods 20 patients with advanced metastatic breast cancer were given following regimen:Vinorelbine 25mg/m2 was given intraveniously in day 1 and day 8,cisplatin 75mg/m2 was given intraveniously in day 1 or 25mg/m2 was given intraveniously in day1 to day 3,repeated every 3 weeks.Evaluation of response and adverse reactions were practiced every 2 cycles.Results 20 patients were evaluable,among them,2 cases reach CR,8 cases PR,4 cases SD and 6 cases PD,with a median followup of 6 months(4 ～ 18months),16 patients survived and 4 patients died.The median time to progression and the median survival time was 5 months(3 ～ 15 months) and 8 months(4 ～ 18 months) respectively.The treatment well tolerated,The main toxicity was myelosuppression and gastrointestinal reaction with WHO grade Ⅲ～Ⅳ gastrointestinal reaction,neutropena and thrombocytopenia being in 25% 、65% and 10% .Conclusion The regimen of NP is safe and effective in treating advanced metastatic breast cancer resisting to anthracycline and taxane.In addition,it was able to improve survival rate and adverse reactions could be tolerated.
